10-K: Supernus Pharmaceuticals Reports 2025 Net Loss Amidst Strategic Acquisitions and Generic Pressures

Supernus Pharmaceuticals reported a net loss of $38.6 million in 2025, driven by the Sage Therapeutics acquisition and increased expenses, despite growth in key product sales and new product launches.

Summary

• Reported a net loss of $38.6 million for the year ended December 31, 2025, a significant decrease from net earnings of $73.9 million in 2024.
• Total revenues increased by 9% to $719.0 million in 2025 from $661.8 million in 2024, primarily due to the Sage acquisition and increased royalty/licensing revenues.
• Net product sales decreased by $11.2 million to $626.5 million in 2025, mainly due to generic erosion for Oxtellar XR and Trokendi XR, and lower APOKYN volume.
• Qelbree net product sales grew by 26% to $304.7 million, and GOCOVRI sales increased by 12% to $146.8 million in 2025.
• Launched ONAPGO in April 2025, generating $17.3 million in net product sales, but faced supplier constraints impacting demand in Q4 2025.
• Acquired Sage Therapeutics on July 31, 2025, for approximately $561 million in cash plus up to $234 million in contingent value rights (CVRs), adding ZURZUVAE to the portfolio.
• ZURZUVAE, an oral treatment for postpartum depression (PPD), became commercially available in the U.S. in December 2023 and contributed $53.0 million in collaboration revenue in 2025.
• Research and development expenses decreased slightly by 2% to $106.2 million in 2025, while selling, general, and administrative expenses surged by 51% to $485.6 million due to acquisition-related costs and new product launches.
• Contingent consideration loss was $25.4 million in 2025, compared to a gain of $6.1 million in 2024, primarily due to the increased fair value of Sage CVRs following ZURZUVAE's MDD approval in Japan.
• Cash and cash equivalents, marketable securities, and restricted cash totaled $310.1 million as of December 31, 2025, down from $453.6 million in 2024, largely due to funding the Sage acquisition.
• The company is involved in multiple patent infringement lawsuits for Qelbree and an antitrust lawsuit concerning APOKYN, as well as securities and derivative litigation related to the Sage acquisition.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025, after remediating material weaknesses identified in 2022.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging period marked by significant acquisition-related expenses and the impact of generic competition on established products, leading to a net loss. While new product launches and strategic acquisitions offer future growth potential, current financial performance and ongoing legal/supply challenges temper the immediate outlook.

Positives

• Qelbree net product sales increased by 26% to $304.7 million in 2025, demonstrating strong growth for the ADHD treatment.
• GOCOVRI net product sales increased by 12% to $146.8 million in 2025, indicating continued demand for the Parkinson's disease treatment.
• Successfully launched ONAPGO in April 2025, a new subcutaneous apomorphine infusion device for advanced Parkinson's disease, generating $17.3 million in sales.
• Acquisition of Sage Therapeutics in July 2025 expanded the neuroscience portfolio with ZURZUVAE, the first oral treatment for postpartum depression (PPD), and contributed $53.0 million in collaboration revenue.
• ZURZUVAE received regulatory approval for the treatment of Major Depressive Disorder (MDD) in Japan in December 2025, and for PPD in Europe, the U.K., and Canada in Q3 and Q4 2025, respectively, expanding international market potential.
• Secured additional product supply for ONAPGO from the current supplier and is working with a second supplier expected to begin supplying in 2027, addressing initial supply constraints.
• Royalty, licensing, and other revenues increased by 63% to $39.4 million in 2025, driven by a regulatory milestone achievement under the Shionogi collaboration agreement.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025, after successfully remediating material weaknesses identified in 2022.

Negatives

• Reported a net loss of $38.6 million in 2025, a significant decline from $73.9 million in net earnings in 2024.
• Net product sales decreased by $11.2 million (2%) in 2025, primarily due to generic erosion for Oxtellar XR and Trokendi XR, and lower APOKYN volume.
• Oxtellar XR net product sales declined by 59% to $40.7 million in 2025 due to generic competition that began in September 2024.
• Trokendi XR net product sales declined by 33% to $42.4 million in 2025 due to generic competition that began in January 2023.
• APOKYN net product sales decreased by 35% to $47.8 million in 2025 due to lower volume and competition from generic versions and other advanced PD treatments.
• SPN-820 Phase 2b study for treatment-resistant depression did not demonstrate a statistically significant improvement on primary and secondary endpoints, leading to a follow-on study with intermittent dosing.
• General and administrative expenses increased by 109% to $196.9 million in 2025, largely due to $72.9 million in one-time acquisition-related costs for the Sage acquisition.
• Contingent consideration resulted in a $25.4 million loss in 2025, compared to a $6.1 million gain in 2024, primarily due to the revaluation of Sage CVRs.
• Marketable securities decreased from $384.3 million in 2024 to $180.2 million in 2025, as proceeds were used to partially fund the Sage acquisition.
• The company expects the royalty term for Orenitram to cease in 2027, which may result in a future decrease to royalty revenues.
• The company will not receive royalties from Namzaric sales after January 2025 due to the entry of a generic version.

Risks

• Dependence on the commercial success of existing products (Qelbree, GOCOVRI, Oxtellar XR, APOKYN, ZURZUVAE) and vulnerability to changes in prescription growth rates, unexpected side effects, loss of intellectual property protection, supply chain shortages, and adverse publicity.
• Risk of material harm from generic or other competitive versions of products, as seen with Trokendi XR and Oxtellar XR, and anticipated for XADAGO in December 2027.
• Uncertainty regarding payment or managed care reimbursement policies, which could hinder or prevent commercial success and force significant product discounts.
• Reliance on a few major wholesalers, distributors, and specialty pharmacies (Cencora, Cardinal Health, McKesson Corporation collectively accounted for over 76% of total product revenue in 2025), with the loss of any potentially harming the business.
• Potential for delays, limitations, or denial of final marketing approval for product candidates or additional indications for existing products by the FDA or other regulatory authorities.
• Reliance on outsourcing for critical activities, including manufacturing and clinical research, which carries risks of non-compliance, sanctions, breaches of agreements, and supply chain disruptions (e.g., ONAPGO supplier constraints).
• Failure to obtain marketing exclusivity for product candidates could allow competitors to enter the market more easily, reducing future revenues.
• Intense competition from large pharmaceutical and biotechnology companies, academic institutions, and other research organizations, which may develop more effective, better-tolerated, or less costly alternatives.
• Products and product candidates may cause undesirable side effects or have other characteristics that limit commercial potential, delay regulatory approval, or lead to product liability claims.
• Inability to obtain or maintain the benefits associated with orphan drug designation, including market exclusivity, due to failure to maintain status or competition.
• Healthcare reform measures (e.g., IRA, OBBBA) could adversely impact pricing, reimbursement, and access to products, potentially reducing profitability.
• Non-compliance with healthcare regulations (e.g., anti-kickback, false claims, patient data privacy) could lead to significant compliance expenses, substantial penalties, and fines.
• Involvement in additional lawsuits to protect or enforce patents (e.g., Qelbree patent litigation) or defend against infringement claims, which can be costly, time-consuming, and distracting.
• Limitations on patent rights may limit the ability to prevent third parties from competing.
• Potential for product liability claims from the use of product candidates in clinical trials and commercial sale of products, which could result in substantial liabilities not fully covered by insurance.
• Difficulties in managing growth, including integrating acquisitions (e.g., Sage Therapeutics), recruiting and retaining talented employees, and maintaining adequate infrastructure.
• Cybersecurity incidents could adversely impact financial condition, results of operations, and reputation, despite implemented security measures and cyber insurance.
• Dependence on key executives, particularly the President and CEO, Jack A. Khattar, with failure in succession planning or retention posing a risk to future performance.
• Business involves hazardous materials, and non-compliance with environmental laws or accidental contamination could lead to liabilities and business interruptions.
• Restrictive covenants from the 2005 asset purchase agreement with Shire (now Takeda) could limit future business opportunities related to specific drug compounds.
• Health pandemics could result in workforce limitations, travel restrictions, delays in clinical trials, supply chain disruptions, and adverse economic impacts.
• Ongoing legal actions and proceedings (e.g., APOKYN antitrust, Sage securities/derivative litigation, SEC investigation) could distract management and result in substantial costs or large judgments.
• Unstable market and economic conditions, including inflation and geopolitical events, may adversely affect business, financial condition, and stock price, and make future financing more difficult.
• Ability to use net operating loss carryforwards and other tax attributes may be limited or expire prior to utilization due to ownership changes or tax law changes (e.g., Section 382, Section 174).

Future Outlook

The company expects continued profitability in future years, though with significant year-to-year variability due to market and payor pressures, generic competition, R&D funding for product candidates, and marketing for new launches like ONAPGO and ZURZUVAE. It plans to initiate Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) studies for SPN-443 in the second half of 2026 and is working to secure a second supplier for ONAPGO by 2027. The royalty term for Orenitram is expected to cease in 2027, potentially decreasing future royalty revenues. The company will continue to actively manage its capital structure and consider financing opportunities for business development.

Management Comments

• Our mission is to improve the lives of patients suffering from CNS diseases.
• Our vision is to be a leader in the CNS industry by developing and commercializing new medicines for the treatment of CNS diseases.
• We continue to drive the revenue growth of our key marketed products.
• We continue to evaluate and develop additional CNS product candidates that we believe have significant commercial potential through our internal research and development efforts.
• We actively explore a broad range of strategic opportunities, including in-licensing products, co-promotion/co-development partnerships, and acquisitions.
• We believe our current sales forces in the U.S. are effectively targeting healthcare providers to support and grow our key commercial products.
• We believe extended-release products, particularly Trokendi XR and Oxtellar XR, may offer important advantages in the treatment of epilepsy.
• We are committed to maintaining and improving our cybersecurity risk management program as our business and the cybersecurity threat environment evolves.
• We consider the intellectual capital of our employees to be an essential driver of our business and key to our future prospects.
• We believe a hazard-free environment is critical for the success of our business.
• We believe a collaborative workplace results in business growth and encourages increased innovation.
• We believe that our existing financing sources, including the Credit Line, are adequate for our current operations, along with cash generated from ongoing operations and continued access to debt markets, will be sufficient to satisfy its cash requirements over the next twelve months and beyond.

Industry Context

StockSavvy.ai notes that Supernus Pharmaceuticals operates in a highly competitive and rapidly changing CNS pharmaceutical industry. The company's strategy of acquiring and developing novel treatments for conditions like ADHD, Parkinson's Disease, and PPD aligns with the industry's focus on addressing unmet medical needs in neuroscience. However, the industry faces increasing pressures from generic competition, healthcare cost containment legislation (e.g., IRA, OBBBA), and evolving regulatory landscapes. The company's recent acquisition of Sage Therapeutics and the launch of ZURZUVAE for PPD position it in a growing market segment, but also expose it to intense competition from existing and pipeline therapies. The challenges with ONAPGO supply chain highlight the inherent manufacturing risks in the pharmaceutical sector, while ongoing patent litigation underscores the critical importance of intellectual property defense against generic entrants.

Comparison to Industry Standards

• The company's strategy of acquiring and in-licensing products, such as Sage Therapeutics for ZURZUVAE, is a common industry practice for expanding portfolios and market reach, comparable to moves by larger pharmaceutical players seeking to diversify and grow in specialized therapeutic areas.
• The rapid entry of generic versions for Trokendi XR and Oxtellar XR, and the anticipated entry for XADAGO, is standard in the pharmaceutical industry once patent exclusivity is lost, leading to significant revenue erosion for branded products.
• The challenges faced by SPN-820 in its Phase 2b study for treatment-resistant depression, with no statistically significant improvement on primary/secondary endpoints, are typical of the high failure rates (often exceeding 85%) in late-stage clinical development for CNS disorders across the industry.
• The company's reliance on third-party contract manufacturing organizations (CMOs) for all manufacturing operations is a common model in the biopharmaceutical industry, allowing companies to focus on R&D and commercialization, but it introduces supply chain risks as demonstrated by the ONAPGO constraints.
• The company's investment in proprietary technology platforms like Microtrol, Solutrol, and EnSoTrol to improve drug profiles (e.g., extended-release, improved adherence) is a recognized strategy for product differentiation and life cycle management, similar to approaches used by companies like Shire (now Takeda) for products like Adderall XR and Intuniv.
• The ongoing patent litigation against generic drug makers for Qelbree is a standard defense mechanism employed by pharmaceutical companies to protect intellectual property and extend market exclusivity, mirroring numerous cases seen with other branded drugs facing ANDA challenges.

Corporate Governance

Legal Proceedings

• **Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited, et al. (Trokendi XR)**: Lawsuit filed March 26, 2021, alleging infringement of Trokendi XR patents by Ajanta's generic ANDA. Settled on April 4, 2023, with a stipulation of dismissal.
• **Supernus Pharmaceuticals, Inc. v. Torrent Pharmaceuticals Ltd., et al. (Trokendi XR)**: Lawsuit filed July 28, 2021, alleging infringement of Trokendi XR patents by Torrent's generic ANDA. District Court ruled in Supernus's favor on January 30, 2024, finding patents valid and infringed. Torrent appealed, but the case was settled on November 5, 2025, and the appeal was dismissed.
• **Sage Chemical, Inc., et al. v. Supernus Pharmaceuticals, Inc., et al. (APOKYN Antitrust)**: Lawsuit filed October 3, 2022, alleging state and federal antitrust law violations related to APOKYN. Motions to dismiss were largely denied in May/June 2024, and a second amended complaint was filed in December 2024. Trial is scheduled to begin January 25, 2027.
• **Supernus Pharmaceuticals, Inc. v. Appco Pharma LLC, et al. (Qelbree Patent Litigation)**: Lawsuit filed June 26, 2025, alleging infringement of Qelbree patents by Appco and Somerset's generic ANDAs. An automatic 30-month stay prevents FDA approval until October 2, 2028. Consolidated with other Qelbree patent lawsuits.
• **Supernus Pharmaceuticals, Inc. v. Aurobindo Pharma Ltd., et al. (Qelbree Patent Litigation)**: Lawsuit filed June 26, 2025, alleging infringement of Qelbree patents by Aurobindo's generic ANDA. An automatic 30-month stay prevents FDA approval until October 2, 2028. Consolidated with other Qelbree patent lawsuits.
• **Supernus Pharmaceuticals, Inc. v. Apotex Inc. (Qelbree Patent Litigation)**: Lawsuit filed June 26, 2025, alleging infringement of Qelbree patents by Apotex's generic ANDA. An automatic 30-month stay prevents FDA approval until October 2, 2028. Consolidated with other Qelbree patent lawsuits.
• **Supernus Pharmaceuticals, Inc. v. Zydus Lifesciences Global FZE, et al. (Qelbree Patent Litigation)**: Lawsuit filed June 26, 2025, alleging infringement of Qelbree patents by Zydus's generic ANDA. An automatic 30-month stay prevents FDA approval until October 2, 2028. Consolidated with other Qelbree patent lawsuits.
• **Supernus Pharmaceuticals, Inc. v. Creekwood Pharmaceuticals, LLC (Qelbree Patent Litigation)**: Lawsuit filed July 11, 2025, alleging infringement of Qelbree patents by Creekwood's generic ANDA. An automatic 30-month stay prevents FDA approval until October 2, 2028. Consolidated with other Qelbree patent lawsuits.
• **Supernus Pharmaceuticals, Inc. v. MSN Pharmaceuticals Inc. (Qelbree Patent Litigation)**: Lawsuit filed July 11, 2025, alleging infringement of Qelbree patents by MSN's generic ANDA. An automatic 30-month stay prevents FDA approval until October 2, 2028. Consolidated with other Qelbree patent lawsuits.
• **Supernus Pharmaceuticals, Inc. v. Zenara Pharma Private Ltd., et al. (Qelbree Patent Litigation)**: Lawsuit filed July 11, 2025, alleging infringement of Qelbree patents by Zenara and Biophore's generic ANDA. An automatic 30-month stay prevents FDA approval until October 2, 2028. Consolidated with other Qelbree patent lawsuits.
• **Supernus Pharmaceuticals, Inc. v. Macleods Pharmaceuticals Ltd., et al. (Qelbree Patent Litigation)**: Lawsuit filed September 9, 2025, and December 16, 2025, alleging infringement of Qelbree patents by Macleods' generic ANDAs. An automatic 30-month stay prevents FDA approval until October 2, 2028. Consolidated with other Qelbree patent lawsuits.
• **US WorldMeds Partners, LLC v. Federal Insurance Company, et al. (Insurance Coverage)**: Lawsuit filed by alleged competitors against Supernus subsidiaries, leading to a dispute over insurance coverage. Consolidated with related actions, discovery is ongoing.
• **US WorldMeds Partners, LLC v. Supernus Pharmaceuticals, Inc. (Milestone Payment Dispute)**: Lawsuit filed May 21, 2025, by US WorldMeds Partners, LLC seeking payment of a withheld $27.7 million milestone payment related to the USWM Acquisition. Oral argument scheduled for March 4, 2026.
• **Adamas Litigation (NAMENDA XR/Namzaric Qui Tam)**: Lawsuit filed April 1, 2019, alleging federal and state false claims acts violations related to NAMENDA XR and Namzaric patents. Ninth Circuit affirmed dismissal of the Federal False Claims Act claim on January 29, 2025. Plaintiff opted not to seek Supreme Court review, but state-law claims may be refiled.
• **Sage Therapeutics Litigation (Securities Class Action)**: Lawsuit filed August 28, 2024, alleging violations of U.S. securities laws against Sage and former officers. Motion to dismiss pending as of January 9, 2026.
• **Sage Therapeutics Litigation (SEC Investigation)**: Sage received a subpoena on October 16, 2024, from the SEC Enforcement Division requesting documents related to its NDA for zuranolone for MDD.
• **Sage Therapeutics Litigation (Consolidated Derivative Litigations)**: Multiple derivative lawsuits filed in March-May 2025, alleging breaches of fiduciary duty, unjust enrichment, and waste of corporate assets, consolidated in June 2025. Stayed pending resolution of the Securities Class Action.
• **Sage Therapeutics Litigation (Merger Complaints)**: Two complaints filed in July 2025 by purported stockholders alleging negligent misrepresentation and concealment related to the Sage acquisition. Seek injunction or damages.

Related Party Transactions

• The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH (Biogen) for the joint development and commercialization of ZURZUVAE in the U.S., with Biogen recording product sales and the company sharing equally in operating profits and losses.
• The company has a collaboration agreement with Shionogi & Co., Ltd. (Shionogi) for the development and commercialization of zuranolone in Japan, South Korea, and Taiwan, with the company eligible for milestone payments and tiered royalties on sales.
• The company has a development agreement with Navitor Pharmaceuticals, Inc. (Navitor Inc.) for SPN-820 (NV-5138), bearing Phase 1 and Phase 2 development costs up to $50 million and holding an option to acquire or license NV-5138, with potential future milestone payments.
• The company has licensing agreements with other companies, including United Therapeutics Corporation and Takeda Pharmaceuticals Company Ltd., for the use of its proprietary technologies, receiving royalties and in some cases, milestone payments (e.g., Orenitram royalties expected to cease in 2027).
• The company has entered into settlement and licensing agreements with generic companies for Trokendi XR and Oxtellar XR, entitling it to receive royalties on generic sales under certain arrangements.
• The company makes royalty payments to Elan Pharmaceuticals, LLC (a subsidiary of Perrigo Pharma International DAC) based on U.S. annual net sales of MYOBLOC.

Stakeholder Impact

• **Shareholders**: Experienced a net loss in 2025, which could negatively impact investor sentiment. The stock price may fluctuate significantly due to generic competition, R&D outcomes, and ongoing litigation. Dilution is a risk from future equity issuances or exercise of outstanding options.
• **Employees**: Increased headcount from 674 in 2024 to 778 in 2025, partly due to the Sage acquisition. The company emphasizes attracting, retaining, and developing talent through competitive compensation, benefits, and a collaborative work environment. However, intense competition for skilled personnel and high cost of living in the Washington D.C. area pose retention challenges.
• **Customers (Wholesalers, Specialty Pharmacies, Distributors)**: The majority of product sales are to a few major customers (Cencora, Cardinal Health, McKesson Corporation), making the company dependent on these relationships. Supply constraints for products like ONAPGO can impact product availability for customers.
• **Patients**: The company's mission is to improve the lives of patients with CNS diseases through new and existing treatments. New product launches like ONAPGO and ZURZUVAE offer new treatment options, but supply constraints or adverse side effects could impact patient access or safety.
• **Suppliers/CMOs**: The company relies heavily on third-party CMOs for manufacturing, creating a dependency. Supply constraints (e.g., ONAPGO) highlight the risks of this reliance, potentially impacting product availability.
• **Creditors**: Indebtedness and liabilities could limit cash flow available for operations, although the company believes its existing financing sources are adequate for current operations. The Credit Line is uncommitted and can be terminated by the lender, posing a risk to liquidity.

Next Steps

• Continue to drive revenue growth of key marketed products (Qelbree, GOCOVRI).
• Advance product candidates toward commercialization, including SPN-817, SPN-820 (follow-on Phase 2b study with intermittent dosing), and SPN-443 (initiate SAD and MAD studies in H2 2026).
• Continue to grow the pipeline through internal R&D efforts.
• Target strategic business development opportunities, including in-licensing, co-promotion, co-development, and acquisitions.
• Secure additional product supply for ONAPGO, with a second supplier expected in 2027.
• Monitor and manage the commercialization of ZURZUVAE in the U.S. with Biogen, and in Japan with Shionogi.
• Defend intellectual property rights in ongoing patent litigation for Qelbree and other products.
• Address ongoing legal proceedings, including the APOKYN antitrust lawsuit and Sage-related securities/derivative litigation.
• Finalize purchase price allocation for the Sage acquisition within one year of the July 31, 2025, closing date.
• Pay $10.0 million to former Biscayne security holders by June 30, 2026, for developmental milestones related to SPN-817.

Key Dates

Recommendation

Supernus Pharmaceuticals is in a transitional phase, marked by significant strategic acquisitions like Sage Therapeutics, which introduces new growth drivers such as ZURZUVAE. However, this growth is currently offset by substantial acquisition-related expenses, ongoing generic erosion of established products like Oxtellar XR and Trokendi XR, and R&D setbacks for pipeline candidates like SPN-820. The net loss in 2025 and reduced operating cash flow reflect these challenges. While the company has a diverse CNS portfolio and is actively defending its intellectual property, the numerous legal proceedings and supply chain issues for new products like ONAPGO introduce considerable uncertainty. The long-term potential of ZURZUVAE and other pipeline assets is promising, but the immediate financial headwinds and execution risks warrant a cautious 'hold' stance for seasoned investors, awaiting clearer signs of sustained profitability and successful integration of new assets.

Keywords

Supernus Pharmaceuticals, CNS diseases, ADHD, Parkinson's Disease, Postpartum Depression, Epilepsy, Migraine, Qelbree, GOCOVRI, ONAPGO, ZURZUVAE, APOKYN, Trokendi XR, Oxtellar XR, XADAGO, MYOBLOC, Sage Therapeutics acquisition, Biogen collaboration, Shionogi collaboration, Pharmaceuticals, Biopharmaceutical, SEC filing, 10-K, Financial results, Drug development, Clinical trials, Generic competition, Patent litigation, Regulatory approval, Healthcare reform, Cybersecurity